NWMG
RXRX icon

National Wealth Management Group’s Recursion Pharmaceuticals RXRX Stock Holding History

National Wealth Management Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.8K Hold
25,000
– – 0.03% 225
2026
Q1 		$76.8K Buy
+25,000
New +$96.6K 0.03% 214

Other funds holding RXRX

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return
SFS
Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return
KG
Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return
TMC
Themes Management Co Greenwich, Connecticut $151M AUM
PL
Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
AWM
Accel Wealth Management Waverly, Iowa $444M AUM 31.14% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
WPC
Wedmont Private Capital West Chester, Pennsylvania $3.65B AUM 26.64% 1-Year Est. Return

National Wealth Management Group's RXRX Position: Q2 2026 in Review

National Wealth Management Group held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 25,000 shares worth $91.8K. The position accounts for 0.03% of the portfolio, ranked #225.

National Wealth Management Group first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 37 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • National Wealth Management Group held 25,000 shares of Recursion Pharmaceuticals worth $91.8K as of Q2 2026.
  • National Wealth Management Group left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up 0.03% of National Wealth Management Group's portfolio in Q2 2026, its #225 holding.
  • National Wealth Management Group first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 37 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on National Wealth Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.